Nova (NVMI) Q3 2026 Earnings Call Transcript

Nova reported Q3 2026 revenue of $287.8 million, up 28% year over year and 13% sequentially, marking its third consecutive record quarter; non-GAAP EPS was $2.86 and non-GAAP operating margin was 35.5%, above the company’s 28%-33% target range. It expects Q4 revenue of $305 million-$315 million and non-GAAP EPS of $3.03-$3.18, and said trailing 12-month revenue exceeded $1 billion a year ahead of plan. Management cited strong DRAM, advanced packaging and gate-all-around demand, while warning that rapid industry growth is stretching the supply chain and that XPS-focused competitors may emerge in the second half of 2027. Nova repurchased $38.5 million of shares during the quarter under its $200 million authorization.

Analysis

Analysis The key change is not simply faster equipment demand: Nova’s opportunity is increasingly tied to process-control intensity, so a richer mix of GAA, advanced DRAM and HBM could let NVMI grow faster than wafer-fab-equipment spending. That mix sensitivity cuts both ways—if customers defer advanced-node projects or memory capacity, Nova can underperform even while aggregate semiconductor investment remains healthy.

The near-term constraint is execution, not reported gross-margin deterioration: stretched suppliers could delay shipments and shift revenue between quarters. The planned Asia clean room may improve capacity and resilience over time, but adds no immediate protection until operational and qualified. Strong financial income from the cash balance supports EPS, but should not be mistaken for recurring operating leverage.

Over the next 6–18 months, the main upside catalysts are conversion of GAA/DRAM intensity into shipped tools and broader adoption of advanced-packaging and chemical-metrology platforms. Adoption or evaluation is not equivalent to repeat high-volume orders; track customer qualification-to-production conversion. The prospective XPS entrants are a later risk, expected around H2 2027, and could pressure pricing or share if Nova’s performance/cost advantage narrows. KLA is relevant in front-end chemical metrology, but the call provides no evidence to support a relative-value short.

Contrarian point: record results and early strategic milestones can obscure customer and territory concentration, while annualized growth may be unusually sensitive to investment mix. Without valuation and current price data, the earnings signal supports a staged exposure, not an unconditional chase.

Key Decisions for Investors

• For existing NVMI exposure, retain a positive bias but size against semiconductor-capex cyclicality; add in tranches on weakness rather than extrapolating the quarter. No price target is supportable from the supplied data.
• Over the next 1–3 months, monitor shipments versus the Q4 revenue outlook and non-GAAP gross margin near 59%. A miss below the revenue guidance floor, sustained margin slippage, or evidence supplier constraints are pushing out deliveries would weaken the thesis.
• Track 2027 conversion of GAA, advanced-DRAM and HBM demand into orders and production deployments—not just evaluations—and whether the remaining Metrion customer qualifies. Weak conversion would falsify the intensity-led outperformance case.
• Treat H2 2027 XPS competition as a watch item, not an immediate short signal. Reassess if entrants win production qualifications or Nova signals pricing pressure, share loss, or a reduced technology/cost-of-ownership gap.